Kala Bio, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Follow-Up Questions
KALA BIO Inc의 CEO는 누구입니까?
Mr. Mark Iwicki은 2015부터 회사에 합류한 KALA BIO Inc의 Chairman of the Board입니다.
KALA 주식의 가격 성능은 어떻습니까?
KALA의 현재 가격은 $1.32이며, 전 거래일에 increased 1.14% 하였습니다.
KALA BIO Inc의 주요 사업 주제나 업종은 무엇입니까?
KALA BIO Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
KALA BIO Inc의 시가총액은 얼마입니까?
KALA BIO Inc의 현재 시가총액은 $9.3M입니다
KALA BIO Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 6명의 분석가가 KALA BIO Inc에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 4명의 강력한 매도를 포함합니다
